IMTX vs JANX: fair value comparison
Immatics N.V. and Janux Therapeutics, Inc. · Updated 2026-10-19
IMTX reports in EUR, so no same-currency fair-value verdict is published for it. JANX has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, IMTX currently ranks higher by quality score.
| IMTX | JANX | |
|---|---|---|
| Verdict | Awaiting full valuation | No estimate yet |
| Last price | $8.44 | $16.51 |
| 12-month range | $6.73–$11.87 | $12.18–$34.74 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #102 of 301 Healthcare | #104 of 301 Healthcare |
| Quality grade | C | C |
| Leverage | Low | Low |
| Margin trend | Stable | Expanding |
| Revenue growth | Strong | High |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | Downtrend | Mixed |
| 52-week position | The lower-middle quarter | The bottom quarter |
Full single-stock breakdowns: IMTX fair value analysis · JANX fair value analysis